Literature DB >> 9430247

Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.

L J Boots1, P M McKenna, B A Arnold, P M Keller, M K Gorny, S Zolla-Pazner, J E Robinson, A J Conley.   

Abstract

A phage display library screening approach was used to identify peptide sequences that could bind to anti-HIV-1 MAbs whose binding specificities are complex. Most of the antibodies used recognize discontinuous epitopes in gp120 and one recognizes gp41. Both a 15-mer and a 21-mer display library (each with a complexity of greater than 60 x 10[6]) and two constrained, V3 region-biased libraries, all expressed as recombinant pIII protein of filamentous phage, were used. The unmapped anti-gp120 human MAb A32 recognized a set of related linear sequences and repeatedly identified a single phage sequence that could form a cyclic disulfide structure. Selection methods were also developed so that phage could be obtained by competition selection in the presence of antibody bound to native, monomeric gp120 antigen (used with MAb IgG1b12 and the anti-gp120 V3 region MAb 447-52D) or gp120 variable region 3 synthetic peptides (used with anti-gp120 V3 region MAb 19b). The potent, virus-neutralizing MAb IgG1b12 recognized numerous sequences and, when used in competition with gp120, recognized only one sequence. These studies extend the range of antibody determinant studies that can be performed with display phage libraries, demonstrate a workable experimental strategy for use of competition ligands to discriminate among phage mimotopes, and provide a large number of mimotopes that bind potent virus-neutralizing MAbs for HIV-1 vaccine studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9430247     DOI: 10.1089/aid.1997.13.1549

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  17 in total

1.  Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells.

Authors:  Andrés Finzi; Beatriz Pacheco; Xin Zeng; Young Do Kwon; Peter D Kwong; Joseph Sodroski
Journal:  J Virol Methods       Date:  2010-05-13       Impact factor: 2.014

2.  A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.

Authors:  Peng Fei Zhang; Peter Bouma; Eun Ju Park; Joseph B Margolick; James E Robinson; Susan Zolla-Pazner; Michael N Flora; Gerald V Quinnan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Long-Acting BMS-378806 Analogues Stabilize the State-1 Conformation of the Human Immunodeficiency Virus Type 1 Envelope Glycoproteins.

Authors:  Shitao Zou; Shijian Zhang; Althea Gaffney; Haitao Ding; Maolin Lu; Jonathan R Grover; Mark Farrell; Hanh T Nguyen; Connie Zhao; Saumya Anang; Meiqing Zhao; Mohammadjavad Mohammadi; Scott C Blanchard; Cameron Abrams; Navid Madani; Walther Mothes; John C Kappes; Amos B Smith; Joseph Sodroski
Journal:  J Virol       Date:  2020-05-04       Impact factor: 5.103

4.  Synthesis of a trimeric gp120 epitope mimic conjugated to a T-helper peptide to improve antigenicity.

Authors:  Joan G Schellinger; Lieza M Danan-Leon; Jessica A Hoch; Aemro Kassa; Indresh Srivastava; David Davis; Jacquelyn Gervay-Hague
Journal:  J Am Chem Soc       Date:  2011-02-22       Impact factor: 15.419

Review 5.  Neutralizing antibodies mechanism of neutralization and protective activity against HIV-1.

Authors:  Yi Xiao; Xiaonan Dong; Ying-Hua Chen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

6.  A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.

Authors:  E J Park; M K Gorny; S Zolla-Pazner; G V Quinnan
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions.

Authors:  Ralph Pantophlet; Meng Wang; Rowena O Aguilar-Sino; Dennis R Burton
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

8.  Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1.

Authors:  Peter Bouma; Maria Leavitt; Peng Fei Zhang; Igor A Sidorov; Dimiter S Dimitrov; Gerald V Quinnan
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

9.  Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model.

Authors:  William L Ince; Liguo Zhang; Qi Jiang; Kathryn Arrildt; Lishan Su; Ronald Swanstrom
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

10.  A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein.

Authors:  Hanna C Kelker; Vincenza R Itri; Fred T Valentine
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.